Research identifies cells that may be responsible for prostate cancer recurrence

December 22, 2017, Roswell Park Cancer Institute
Research identifies cells that may be responsible for prostate cancer recurrence
Slide illustrating resistance to androgen-deprivation therapy in a newly identified population of dormant prostate luminal stem cells. Credit: Roswell Park Cancer Institute

Although men with prostate cancer usually respond to standard treatment with hormone therapy or chemotherapy, many will eventually experience progression or recurrence despite treatment—particularly those with high-risk or aggressive forms of the disease. In preclinical laboratory research, a team led by Dean Tang, Ph.D., Chair of Pharmacology and Therapeutics at Roswell Park Cancer Institute has discovered a unique population of normal stem cells that are intrinsically resistant to conventional treatments and may enable prostate cancer relapse. In a new publication in the journal Stem Cell Reports, the team reports its development of a novel preclinical model that allows not only the labeling but also the purification of this rare but persistent population of prostate stem cells, which are dormant and, strikingly, resemble high-risk prostate cancer at the molecular level.

The normal prostate and most contain a small number of cells called luminal progenitors that, unlike the bulk of cancer cells, are generally dormant. They behave like stem cells, lacking expression of the molecules targeted by current cancer treatments. As a result, these cells evade prostate cancer treatments such as chemotherapy and radiation, which generally target and eliminate cells that are rapidly multiplying and dividing. Unlike most , these dormant, stem-like cells are also less dependent on androgens, making them relatively unresponsive to chemical castration or , approaches designed to "starve" tumors by depriving them of their androgen fuel.

"The existence of a population of quiescent or slow-cycling cells in the prostate has been suggested, but their identity and characteristics were unknown because they are rare and very difficult to study," explains Dingxiao Zhang, Ph.D., an Assistant Professor with the Department of Pharmacology and Therapeutics at Roswell Park and first author on the new study. "We were able to identify a unique population of cells that might serve as the origin of treatment-resistant prostate cancer. Our genetic model paves the way toward the next step, which is the development of therapies that can target these , which are expected to significantly improve the treatment of and delay or even prevent its recurrence."

Explore further: Research helps explain why androgen-deprivation therapy doesn't work for many prostate cancers

More information: Dingxiao Zhang et al. Histone 2B-GFP Label-Retaining Prostate Luminal Cells Possess Progenitor Cell Properties and Are Intrinsically Resistant to Castration, Stem Cell Reports (2017). DOI: 10.1016/j.stemcr.2017.11.016

Related Stories

Research helps explain why androgen-deprivation therapy doesn't work for many prostate cancers

January 5, 2017
Metastatic prostate cancer, or prostate cancer that has spread to other organs, is incurable. In new research published in the journal Science, Roswell Park Cancer Institute scientists have identified two gatekeeper genes ...

Recurrence of prostate cancer could be reduced thanks to exciting new discovery

September 5, 2017
Ground breaking research could reduce the recurrence of prostate cancer in males, a new study in the journal Nature Communications reports.

Study links normal stem cells to aggressive prostate cancer

February 29, 2016
A study that revealed new findings about prostate cells may point to future strategies for treating aggressive and therapy-resistant forms of prostate cancer.

Research team identifies role for a microRNA involved in prostate cancer metastasis

January 25, 2017
Metastasis, or spread of a tumor from the site of origin to additional organs, causes the vast majority of cancer-related deaths, but our understanding of the molecular mechanisms behind metastasis remains limited. A research ...

Study uncovers an additional strategy for targeting treatment-resistant prostate cancer

May 2, 2017
Prostate cancer cells depend on signaling through the androgen receptor (AR) to grow and survive. Many anti-cancer therapies that target ARs are initially successful in patients, including a class of drugs known as CYP17A1 ...

Marker for aggressive prostate cancer doubles up as a drug target

November 8, 2016
Researchers have discovered that a marker found on aggressive prostate cancer cells could also be used as a way to guide treatments to the cancer, according to new research presented at the National Cancer Research Institute ...

Recommended for you

Researchers suggest new treatment for rare inherited cancers

July 16, 2018
Studying two rare inherited cancer syndromes, Yale Cancer Center (YCC) scientists have found the cancers are driven by a breakdown in how cells repair their DNA. The discovery, published today in Nature Genetics, suggests ...

Researchers map 'family trees' of acute myeloid leukemia

July 16, 2018
For the first time, a team of international researchers has mapped the family trees of cancer cells in acute myeloid leukaemia (AML) to understand how this blood cancer responds to a new drug, enasidenib. The work also explains ...

Scientists sharpen the edges of cancer chemotherapy with CRISPR

July 13, 2018
Tackling unsolved problems is a cornerstone of scientific research, propelled by the power and promise of new technologies. Indeed, one of the shiniest tools in the biomedical toolkit these days is the genome editing system ...

Products of omega-3 fatty acid metabolism may have anticancer effects, study shows

July 13, 2018
A class of molecules formed when the body metabolizes omega-3 fatty acids could inhibit cancer's growth and spread, University of Illinois researchers report in a new study in mice. The molecules, called endocannabinoids, ...

Looking at the urine and blood may be best in diagnosing myeloma

July 13, 2018
When it comes to diagnosing a condition in which the plasma cells that normally make antibodies to protect us instead become cancerous, it may be better to look at the urine as well as the serum of our blood for answers, ...

Massive genome havoc in breast cancer is revealed

July 12, 2018
In cancer cells, genetic errors wreak havoc. Misspelled genes, as well as structural variations—larger-scale rearrangements of DNA that can encompass large chunks of chromosomes—disturb carefully balanced mechanisms that ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

CharlesK
not rated yet Jan 10, 2018
I was buying a generic brand from the grocery store, and the best prostate supplement amazon had was this one by alpha rise prostate health. My amazon prime orders always include it in my monthly haul.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.